Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4045 Radio-guided surgery with a new generation β-probe for radiolabelled somatostatin analogue, in patients with small intestinal neuroendocrine tumors – A Phase II surgical trial

Introduction: Radio-guided surgery (RGS) proved to be promising in neuroendocrine tumors (NETs). Previous studies showed high sensitivity but low specificity using gamma probes to detect radiation emitted by radio-labelled somatostatin analogues.

Conference:

Presenting Author: Danieli M

Authors: Bertani E, Fumagalli Romario U, Collamati F, Mattana F, Fazio N,

Keywords: Radio-guided surgery, small-intestinal neuroendocrine tumor, small-intestinal resection, beta-probe, radiolabelled somatostatine analogues, surgery, lymphadenectomy,

#3277 Single-institution experience with 18F-DOPA and 68Ga-DOTA-TOC as a PET imaging tracer for peptide receptor radionuclide therapy in well-differentiated neuroendocrine neoplasms

Introduction: In treatment of neuroendocrine neoplasms (NENs), confirmation of somatostatin receptor affinity with 68Ga-DOTA, is mandatory to determine eligibility for peptide receptor radionuclide therapy (PRRT). 18F-FDOPA tracer is also used in the diagnostic imaging of NENs, likely detecting additional lesions compared to 68Ga-DOTA.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Veenstra E, Noordzij W,

Keywords: neuroendocrine tumor, PET tracer, 18F-DOPA, 68Ga-DOTA-TOC, carbidopa, peptide receptor radionuclide therapy, PRRT,

#3103 Comparison of 18F-DOPA versus 68Ga-DOTA-TOC as preferred PET imaging tracer in well-differentiated neuroendocrine neoplasms

Introduction: 18F-DOPA and 68Ga-DOTA-TOC are two diagnostic PET tracers used in neuroendocrine neoplasms (NENs). As both tracers utilise different metabolic pathways, lesion detection results often show disparities, but comparative studies are lacking.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Veenstra E

Authors: Veenstra E, de Groot D, Brouwers A, Walenkamp A, Noordzij W,

Keywords: neuroendocrine tumor, PET, tracer, 18F-DOPA, 68GA-DOTA-TOC, tumor marker, carbidopa,

#2089 Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Patients with GEP-NETs

Introduction: The majority of patients diagnosed with gastroenteropancreatic (GEP)-NETs present metastases expressing somatostatin receptor 2 (SSTR2). The 68Gallium-labelled SSTR2 antagonist 68Ga-OPS202 has shown improved diagnostic performance as a PET imaging agent compared with the SSTR2 agonist 68Ga-DOTA-TOC in a single-centre study.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Virgolini I, Brouwers A, Haug A, Grønbæk H, Kjær A,

Keywords: 68Ga-OPS202, GEP-NET, SSTR2, optimal dose range,

#1909 68Ga-DOTA-TOC and 18F-FDG-PET/CT in the Follow-up of NET Patients treated with First Full PRRT

Introduction: Only few studies have correlated 18F-FDG and SSTR imaging with NET grade.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Rodrigues M, Nilica B, Waitz D, Stevanovic V, Uprimny C,

Keywords: 68Ga-PET, FDG,